US prostate cancer diagnostic and therapeutic market was valued at $8,250.5 million in 2025 and is projected to reach $20,091.0 million by 2035, growing at a CAGR of 9.4% during the forecast period (2026-2035). Rising prostate cancer incidence in the US is reinforcing long-term demand for advanced diagnostics and therapeutics. According to the American Cancer Society’s Cancer Statistics 2025, prostate cancer incidence increased at the steepest rate among common cancers, rising by approximately 3% annually between 2014 and 2021. In 2025 alone, the US is expected to record about 2.04 million new cancer cases, indicating a sustained and expanding oncology patient pool. This upward trend in prostate cancer diagnoses is directly expanding the addressable market for PSA testing, genomic profiling, PSMA-PET imaging, targeted therapies, radioligand treatments, and next-generation hormonal agents.
Browse the full report description of “UK Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035” at https://www.omrglobal.com/industry-reports/us-prostate-cancer-diagnostic-therapeutic-market
Persistent variations in stage at diagnosis and treatment uptake are increasingly shaping clinical priorities in prostate cancer care. A meaningful proportion of patients are still diagnosed at advanced or metastatic stages, where treatment options are more complex and survival outcomes are significantly lower compared to localized disease. Delays in screening, inconsistent adherence to guidelines, and differences in access to advanced imaging and genomic testing continue to influence patient outcomes. In response, healthcare systems and policymakers are placing greater emphasis on earlier detection strategies, risk-stratified screening, and broader integration of precision diagnostics into routine care. This shift is expected to increase utilization of PSMA-PET imaging, molecular profiling, radioligand therapy, and next-generation hormonal treatments, thereby strengthening long-term demand within the market.
Innovation Leaders Transforming the US Prostate Cancer Diagnostic and Therapeutic Market
The key players in the US prostate cancer diagnostic and therapeutic market include Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson (Janssen), Novartis AG, AstraZeneca plc, among others. These companies are driving innovation in the prostate cancer market through the development of next-generation immunotherapies, PSMA-targeted radiopharmaceuticals, precision imaging agents, and advanced molecular diagnostic platforms. Their focus on improving treatment efficacy, enhancing safety profiles, enabling earlier and more accurate detection, and supporting personalized therapy approaches is accelerating progress in advanced and metastatic prostate cancer care across global healthcare markets.
Market Coverage
Key questions addressed by the report.
US Prostate Cancer Diagnostic and Therapeutic Market Report Segment
By Diagnostic Technique
By Therapeutics
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-prostate-cancer-diagnostic-therapeutic-market